Today, CADTH has issued final recommendations for:
Indications: transthyretin-mediated amyloidosis
Published on: February 21, 2020
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.
Published on: February 13, 2020
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news ...
Published on: February 10, 2020